Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Study includes 5 visits, when all basic clinical information, vital signs, symptoms, and side
effects are going to be assessed at each appointment.
Patients are going to be assigned by the computer, to receive an active or non-active drug
for 14 days in a first phase. The order will be change during the second phase. The 2 weeks
break without our medication will separate these phases. A very close observation regarding
safety of our subjects will be implemented by study personnel and clinical investigators.
Phase:
Phase 4
Details
Lead Sponsor:
Texas Tech University Health Sciences Center, El Paso